James Quigley
Stock Analyst at Morgan Stanley
(0.31)
# 4,230
Out of 4,974 analysts
22
Total ratings
33.33%
Success rate
-18.51%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Upgrades: Overweight | $49 → $79 | $43.50 | +81.61% | 6 | Jun 3, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $46.50 | +39.78% | 1 | Mar 21, 2025 | |
| NVS Novartis AG | Downgrades: Neutral | $119 → $121 | $129.73 | -6.73% | 1 | Sep 5, 2024 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $10.13 | +3.65% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $33.37 | +19.87% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $3.48 | +359.77% | 3 | Jun 23, 2023 |
Kymera Therapeutics
Jun 3, 2025
Upgrades: Overweight
Price Target: $49 → $79
Current: $43.50
Upside: +81.61%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $46.50
Upside: +39.78%
Novartis AG
Sep 5, 2024
Downgrades: Neutral
Price Target: $119 → $121
Current: $129.73
Upside: -6.73%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $10.13
Upside: +3.65%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $33.37
Upside: +19.87%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $3.48
Upside: +359.77%